Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to 0.72.

  • Niagen Bioscience's Equity Ratio rose 1843.52% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year increase of 1843.52%. This contributed to the annual value of 0.68 for FY2024, which is 3039.71% up from last year.
  • As of Q3 2025, Niagen Bioscience's Equity Ratio stood at 0.72, which was up 1843.52% from 0.7 recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Equity Ratio peaked at 0.72 during Q3 2025, and registered a low of 0.45 during Q2 2022.
  • Over the past 5 years, Niagen Bioscience's median Equity Ratio value was 0.54 (recorded in 2021), while the average stood at 0.57.
  • Its Equity Ratio has fluctuated over the past 5 years, first crashed by 3035.59% in 2022, then soared by 3039.71% in 2024.
  • Niagen Bioscience's Equity Ratio (Quarter) stood at 0.55 in 2021, then decreased by 3.3% to 0.53 in 2022, then decreased by 2.39% to 0.52 in 2023, then soared by 30.4% to 0.68 in 2024, then rose by 6.68% to 0.72 in 2025.
  • Its last three reported values are 0.72 in Q3 2025, 0.7 for Q2 2025, and 0.68 during Q1 2025.